|
|
|
|
Influence of Immunosuppressive Therapy on the Natural History of Genotype 3 Hepatitis-E Virus Infection After Organ Transplantation
Background.Hepatitis-E virus (HEV) infection can be responsible for chronic hepatitis in solid-organ transplant patients. Methods. We identified 33 cases of autochthonous acute HEV infection in solid-organ transplant patients. Results.
|
|
|
Inhibition of Inducible Nitric Oxide Synthase Prevents Mitochondrial Damage and Improves Survival of Steatotic Partial Liver Grafts
Background.Steatotic liver grafts are excluded for partial liver transplantation because of increased risk of primary nonfunction. Mechanisms underlying the failure of fatty partial liver grafts (FPG) remain unknown. This study investigated whether...
|
|
|
IOWA: Free HIV and Hepatitis Testing
Thanks to a $13,000 grant, the Cerro Gordo Department of Public Health is offering free HIV and hepatitis C testing to high-risk individuals.Betty Krones, a disease prevention specialist with CGDPH, noted many of those in the target population cannot...
|
|
|
Hepatitis C self-care
If you have hepatitis C your doctor needs to keep close watch on your liver function.iStockphoto.com/Lilli Day Also on the Web myOptumHealth.com tools More from myOptumHealth More>> Health More>> Latest Health News More>> Content...
|
|
|
Novartis gains exclusive rights to Debio 025, an antiviral agent in Phase IIb development as potential first-in-class hepatitis C ..
Novartis International AG / Novartis gains exclusive rights to Debio 025, an antiviral agent in Phase IIb development as potential first-in-class hepatitis C therapy processed and transmitted by Hugin AS.The issuer is solely responsible for the content...
|
|
|
Novartis Gains Exclusive Rights to Debio 025, an Antiviral Agent in Phase IIb Development as Potential First-i
Novartis International AG / Novartis gains exclusive rights to Debio 025, an antiviral agent in Phase IIb development as potential first-in-class hepatitis C therapy processed and transmitted by Hugin AS.The issuer is solely responsible for the content...
|
|
|
Novartis gains exclusive rights to Debio 025, an antiviral agent in Phase IIb development as potential first-in-class hepatitis C therapy
(Hugin via COMTEX) ----Novartis International AG / processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. * Phase II results demonstrate efficacy of Debio 025, a cyclophilin inhibitor, against ...
|
|
|
Novartis gains exclusive rights to Debio 025, an antiviral agent ...
Company: Novartis AG (NVS) Novartis International AG / Novartis gains exclusive rights to Debio 025, an antiviral agent in Phase IIb development as potential first-in-class hepatitis C therapy processed and transmitted by Hugin AS.The issuer is solely...
|
|
|
Novartis gains exclusive rights to Debio 025, an antiviral agent in Phase IIb development as potential first-in-class hepatitis
Novartis International AG / C therapy processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. * Phase II results demonstrate efficacy of Debio 025, a cyclophilin inhibitor, against hepatitis C...
|
|
|
Novartis gains exclusive rights to Debio 025, an antiviral agent in Phase IIb development as potential first-in-class hepatitis C therapy
NOVARTIS AG CHF0.50(REGD) / processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. * Phase II results demonstrate efficacy of Debio 025, a cyclophilin inhibitor, against hepatitis C virus when...
|
|
|
Is hepatitis B virus genotype C independently associated with cirrhosis?
Hepatitis B virus (HBV) genotypes have distinct geographical distributions, and have been shown to differ with regard to clinical outcome and prognosis.However, the relationship between HBV genotypes and liver cirrhosis remains controversial and no...
|
|
|
Novartis International AG (CH) - Novartis Gains Exclusive Rights to Debio 025, an Antiviral Agent in Phase IIb
* Phase II results demonstrate efficacy of Debio 025, a cyclophilin inhibitor, against hepatitis C virus when used alone or in combination with current standard therapy1 * Cyclophilin inhibitors evolving as new class of medicines with potential to become...
|
|
|
Novartis International AG (CH) - Novartis gains exclusive rights to Debio 025, an antiviral agent in Phase IIb
* Phase II results demonstrate efficacy of Debio 025, a cyclophilin inhibitor, against hepatitis C virus when used alone or in combination with current standard therapy1 * Cyclophilin inhibitors evolving as new class of medicines with potential to become...
|
|
|
Novartis gains exclusive rights to Debio 025, an antiviral agent in Phase IIb development as
Novartis International AG / potential first-in-class hepatitis C therapy processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. * Phase II results demonstrate efficacy of Debio 025, a cyclophilin...
|
|
|
Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 0
A Potent, First-in-class Antiviral Agent for the Treatment of Hepatitis C LAUSANNE, Switzerland, February 9/PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of...
|
|
|
Thymosin 4 exhibits potential as new therapeutic agent for liver failure due to chronic HBV infection
REGENERX BIOPHARMACEUTICALS, INC.(NYSE Amex:RGN) announced today that researchers have correlated T4 levels with the clinical course of patients with hepatitis B virus-related liver failure. It was reported that serum thymosin 4 levels were...
|
|
|
Novartis International AG : Novartis gains exclusive rights to Debio 025, a...
Novartis gains exclusive rights to Debio 025, a...Novartis International AG / Novartis gains exclusive rights to Debio 025, an antiviral agent in Phase IIb development as potential first-in-class hepatitis C therapy processed and transmitted by Hugin...
|
|
|
NOVARTIS AG CHF0.50(REGD) : Novartis gains exclusive rights to Debio 025, a...
Novartis gains exclusive rights to Debio 025, a...NOVARTIS AG CHF0.50(REGD) / Novartis gains exclusive rights to Debio 025, an antiviral agent in Phase IIb development as potential first-in-class hepatitis C therapy processed and transmitted by Hugin...
|
|
|
Novartis (NVS) Gains Rights to Develop and Distribute Debio 025; Currently in Phase IIb
Novartis (NYSE: NVS) has gained exclusive rights to develop and market Debio 025 (alisporivir), a potential first-in-class antiviral agent currently in Phase IIb development for the treatment of hepatitis C.Debio 025 is the first in a new class of...
|
|
|
Novartis gains exclusive rights to Debio 025, an antiviral agent in Phase IIb development as pote...
Novartis oral MS therapy FTY720 shows reduced risk of confirmed disability progr...Three new Novartis medicines approved in Japan for patients with type 2 diabetes... Novartis providing equivalent of over USD 2.5 million in immediate emergency aid...
|
|
|
Dynavax Initiates Large-Scale Phase 3 Trial of HEPLISAV(TM)
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today initiation of a large-scale Phase 3 trial designed to demonstrate the lot-to-lot consistency of commercial vaccine and to complete the safety database for HEPLISAV, the Company's investigational...
|
|
|
Entecavir (Baraclude) Improves Liver Function in Chronic Hepatitis B Patients with Decompensated Cirrhosis
Over years or decades, can progress to advanced liver disease including cirrhosis (scarring) and hepatocellular carcinoma.Compensated cirrhosis means the liver is heavily damaged but can still carry out its normal functions; decompensated cirrhosis occurs...
|
|
|
Markers of hepatitis B virus infection and immunity in Victoria, Australia, 1995 to 2005
Objective: Estimating the prevalence of chronic hepatitis B virus (HBV) infection in generally low-prevalence populations containing communities with a higher disease burden is difficult.This study was conducted to estimate the prevalence of...
|
|
|
Online, Personalized STD Test Recommendation is the First Developed by a National Team of Academic and Medical Experts Targeted to College Students an
CHICAGO, Feb.9 /PRNewswire/ -- STDUniversity.org is the first website to provide an interactive, personalized STD test recommendation developed by academic and medical experts. This expert-based tool incorporates screening guidelines from the Centers for...
|
|
|
Dynavax Initiates Large-Scale Phase 3 Trial Of HEPLISAVTM
Dynavax Technologies Corporation (NASDAQ: DVAX) announced initiation of a large-scale Phase 3 trial designed to demonstrate the lot-to-lot consistency of commercial vaccine and to complete the safety database for HEPLISAV, the Company's investigational adult ...
|
